<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing recommendations for oseltamivir for the treatment or prophylaxis of influenza in infants younger than 1 year</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing recommendations for oseltamivir for the treatment or prophylaxis of influenza in infants younger than 1 year</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing recommendations for oseltamivir for the treatment or prophylaxis of influenza in infants younger than 1 year</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Treatment*</td> <td class="subtitle1">Prophylaxis<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Term infants with known body weight</td> </tr> <tr> <td class="indent1">&lt;3 months<sup>Δ</sup></td> <td>3 mg/kg per dose orally twice daily for 5 days</td> <td>Not recommended except in critical situations<sup>◊</sup></td> </tr> <tr> <td class="indent1">3 through 8 months</td> <td>3 mg/kg per dose orally twice daily for 5 days</td> <td>3 mg/kg orally once daily</td> </tr> <tr> <td class="indent1">9 through 11 months</td> <td>3.5 mg/kg per dose orally twice daily for 5 days</td> <td>3.5 mg/kg orally once daily</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Term infants whose body weight is not known</td> </tr> <tr> <td class="indent1">Age 0 through 3 months<sup>Δ</sup></td> <td>12 mg orally twice daily for 5 days</td> <td>Not recommended except in critical situations<sup>◊</sup></td> </tr> <tr> <td class="indent1">Age 4 through 5 months</td> <td>17 mg orally twice daily for 5 days</td> <td>17 mg orally once daily</td> </tr> <tr> <td class="indent1">Age 6 through 11 months</td> <td>24 mg orally twice daily for 5 days</td> <td>24 mg orally once daily</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preterm infants</td> </tr> <tr> <td class="indent1">PMA &lt;28 weeks<sup>Δ</sup></td> <td>Consultation with a specialist in pediatric infectious diseases is recommended</td> <td rowspan="4">Not recommended except in critical situations<sup>◊</sup></td> </tr> <tr> <td class="indent1">PMA 28 through 37 weeks, 6 days</td> <td>1 mg/kg per dose orally twice daily for 5 days</td> </tr> <tr> <td class="indent1">PMA 38 through 40 weeks, 0 days</td> <td>1.5 mg/kg per dose orally twice daily for 5 days</td> </tr> <tr> <td class="indent1">PMA &gt;40 weeks through 8 months chronologic age</td> <td>3 mg/kg per dose orally twice daily for 5 days</td> </tr> <tr> <td class="indent1">Chronologic age 9 months through 11 months</td> <td>3.5 mg/kg per dose orally twice daily for 5 days</td> <td>3.5 mg/kg per dose orally once daily</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on the prevention and treatment of influenza in children. Oseltamivir is supplied as an oral suspension (6 mg/mL). Providers and pharmacists must take care to provide a dosing device that matches the units of measure on the directions provided to the caregiver and that can accurately deliver the dose prescribed. Dose adjustment is necessary for patients with decreased or decreasing glomerular filtration rate. Refer to UpToDate content for additional details (eg, indications for treatment or prophylaxis).</div><div class="graphic_footnotes"><p>PMA: postmenstrual age (gestational age plus chronologic age).</p>
<p>* The usual duration of treatment is 5 days. Hospitalized patients with severe illness and immunocompromised patients may require an extended course of therapy.</p>
<p>¶ The duration of prophylaxis varies with the clinical circumstances.</p>
<p>Δ Although not part of the US Food and Drug Administration-approved indications, use of oral oseltamivir for treatment of influenza in infants less than 14 days old, and for chemoprophylaxis in infants 3 months to 1 year, is recommended by the American Academy of Pediatrics and Centers for Disease Control and Prevention.<sup>[1,2]</sup></p>
◊ Consultation with a specialist in pediatric infectious diseases is recommended.</div><div class="graphic_reference">References:
<ol>
<li>Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2022-2023. Pediatrics 2022; :e2022059274.</li>
<li>Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. Available at <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a> (Accessed September 6, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 129898 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
